Loss Is A Four-Letter Word: Provides The Tools To Help Anyone Who's Lost A Spouse Find Their Own Healing Journey Forward

"Carole Brody Fleet is forthright in dealing with many of the difficult issues surrounding widowhood, demonstrating that you do not have to live in your past. It's not an either-or situation. She teaches the important lesson that you can incorporate your previous life into a new life.”
— Jane Brody, personal health columnist, The New York Times

Deerfield Beach, FL, November 6, 2018 — No widow or widower look exactly the same. No widowhood looks exactly the same. Therefore, no healing journey or timeline is an identical experience. The word "loss” contains only four letters, but its size belies the amount of fear it produces at even its mere mention. Even more terrifying and enormous is the reality of loss–specifically, the loss of a spouse.

Widowhood has the capacity to keep those affected from moving forward into a new and fulfilling life. The loss of a spouse is frightening. The call for relatable and actionable direction and advice remains a very real need for the widowed community, and that is just what Loss is a Four-Letter Word offers. Award-winning author Carole Brody Fleet personally experienced the pain and grief as a young widow and mother; leaving her and her 9-year-old daughter alone. Loss is a Four-Letter Word shows readers a way out, a way to move forward– not "get over”–their most profound loss in positive ways. Fleet combines no-nonsense, direct advice with specific, boot-camp style "assignments” that are framed with compassion and humor to help them through a most challenging life-journey.

A short sample of the Bereavement Boot Camp Lessons:

•   Lesson One: I'm Still Here
•   Lesson Two: "My Healing Journey Is Mine”
•   Lesson Three: Stop Putting Off Proactivity
•   Lesson Four: "I Turn to… Who?”
•   Lesson Five: Put Your Tits on Your Back
•   Lesson Six: Get Up, Get Moving… Get Out!
•   Lesson Seven: It's Your Turn
•   Lesson Eight: Past, Present, and Future: You Can Have All Three

Loss is a Four-Letter Word gives readers help without reproach, education without lecture, and support without judgment, condition, or negative opinion. All of which provides a necessary light during such devastating times. Fleet tells them, "Because while our spouses may have departed this earth, we are still here. And we matter too.”

About the Author:

Carole Brody Fleet is the award-winning author of When Bad Things Happen to Good Women, Happily EVEN After, and Widows Wear Stilettos. Widely recognized as America's go-to expert on life adversity and grief recovery, Ms. Fleet is also a three-time contributor to the iconic Chicken Soup for the Soul book series, as well as a regular contributor to The Huffington Post and to ThirdAge.com. Ms. Fleet is also a popular motivational speaker and with her inimitable message of "What Now and What Next?” Ms. Fleet offers practical, emotional, and even humorous guidance to the millions who have experienced any kind of loss or challenge in their lives.

Loss Is A Four-Letter Word: A Bereavement Boot Camp for the Widowed
By Carole Brody Fleet
ISBN: 9780757321214
September 2018
$15.95
Available wherever books are sold or to order directly from the publisher,

Reviews:

Karen Noé, author, We Consciousness: 33 Profound Truths for Inner and Outer Peace and Your Life After Their Death: A Medium's Guide to Healing After a Loss: "Carole Brody Fleet has done it again! In Loss is a Four Letter Word, she offers practical, straightforward advice on how to move forward on a positive path after losing a loved one. I've had Carole as a guest on the "Angel Quest” radio show a number of times because of how much she has benefited my listeners with her knowledge. If it sounds like I am impressed with her, it's because I am. I love this book, and I love Carole!”

Lisa Lockwood, crime analyst, author, police and military veteran: "What I love and appreciate is Carole Brody Fleet's firsthand knowledge and approach on the most taboo topic in society. Having gone through personal loss, I always learn something about how to approach the topic with empathy and how to permit others to comfort me in the worst of times.”

Stacey Gualandi, Emmy award-winning journalist: "Carole Brody Fleet has faced painful challenges and loss with courage and resilience. Through her own personal healing, we can all learn from and be inspired by her. I have a four-letter word for Carole: HERO.”

Kristin Higson-Hughes, Senior Features Editor, Women's World Magazine: "Just as there is no timetable to grief, there certainly is no checklist on how to recover strength and joy after suffering a loss. Here you will find authentic, candid, trustworthy, and--perhaps most pertinent of all--pragmatic advice promising that although the landscape of life may forever be changed, the future can still hold purpose, beauty, and magic. With a signature style all her own, Carole Brody Fleet "trains" you to find yourself again (hint: there's no wrong path, but some are healthier for your soul!). Together, you will navigate everything from social media to financial matters to the possibility of finding love again. Sure, it can feel impossible to do, and even more so to find answers, but sign up, dear recruit, and discover this book's wit and wisdom, and its author's enormous-as-the-universe heart!"

Kim Iversen, nationally syndicated radio show host: "Carole is an angel, not just an expert. Many of us have no clue what to say to a loved one going through tremendous loss. We sit by and watch helplessly as they struggle with their 'new normal'. Carole's book is a must read; not just for widows, but for those of us who love a widow as well. As a relationship radio talk show host, I have always had words to comfort and guide someone through every type of heartache-----every heartache except the death of a spouse. This type of loss leaves many of us speechless. Finally, someone who knows what to say when the rest of us do not."

Survey Reveals Canadians Largely Unaware of Threat of Antimicrobial Resistance

MISSISSAUGA, ON, Nov. 6, 2018 /CNW/ - In acknowledgement of World Antibiotic Awareness Week, Nov. 12-18, a new survey examining Canadians' understanding of antimicrobial resistance (AMR) reveals that many are unfamiliar with and unconcerned about the threat of drug resistance.^1,2

BD - Canada (CNW Group/BD - Canada)

Drug-resistant infections are predicted to cause more deaths by 2050 than cancer and diabetes today, and without serious collective action, the spread of AMR could lead to an era in which common injuries and infections become lethal.^3,4 With greater education on the topic, Canadians can become better equipped to take an active role in advocating for action against this threat.

The survey revealed:

Only 29 per cent of Canadians surveyed consider themselves "somewhat" or "very" knowledgeable about AMR.²
When asked about their personal overall health and well-being, Canadians ranked AMR among conditions that were of least concern.²
Canadians are interested in learning more about AMR, with 81 per cent of respondents wanting more government information on the topic.²

Results illustrated that many Canadians shared widespread misconceptions relating to AMR. Of those surveyed, 60 per cent of respondents nationwide believed 'antibiotic resistance' means that a person with an infection is resistant to antibiotics.²

"Antimicrobial resistance occurs when bacteria or other microorganisms develop resistance to antibiotics and other antimicrobial drugs," says Dr. David Patrick, University of British Columbia's School of Population and Public Health. "Antibiotic resistance does not refer to a body's resistance to antibiotics, but to the bacteria's response to antibiotics."

The survey also revealed misunderstandings about whether AMR is something Canadians should be worried about. Nationwide, 44 per cent of respondents believed AMR to be more of a concern in developing countries.

"Antimicrobial resistance affects everyone, everywhere, and that includes Canada, where it is an increasingly serious concern," says Dr. Andrew Morris, Sinai Health System and University Health Network. "It is truly a global health issue that warrants collective action."

To play a role in effectively combating AMR, Canadians can discuss their infections with health care providers and the appropriateness of receiving antibiotic treatment.

"Ensuring we're using appropriate antibiotics through strong antimicrobial stewardship programs will allow clinicians and physicians to take action on diagnostic test results, which is an important strategy to reduce unnecessary prescribing and for the early detection of drug-resistant infections," says Steve Gundersen, president, BD – Canada.

BD, a global medical technology company, commissioned the study to determine the state of public awareness and understanding of AMR across Canada. The company is also collaborating with several other entities, to mobilize a new broad-based AMR public awareness and coalition-building campaign, under the theme I'm a resistance fighter™. The global Antimicrobial Resistance Fighter campaign highlights the roles and impact of health practitioners, professional associations, government leaders, non-government organizations, health agencies, advocacy groups and patients in combating AMR. It focuses on communicating the stories and impacts of organizations and clinicians that are combating AMR, and the testimony of patients and their families who have personally battled antimicrobial resistant infections. Canadians interested in sharing their story or joining this campaign can visit: antimicrobialresistancefighters.org.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

Sources:

World Health Organization. World Antibiotic Awareness Week, 12-18 November 2018. Last accessed September 24, 2018. http://www.who.int/campaigns/world-antibiotic-awareness-week/en/.
Leger. Antimicrobial Resistance Awareness Report. 2018.
O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. The Review on Antimicrobial Resistance, Creative Commons Attribution 4.0 International Public License.
World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Last accessed September 19, 2018. http://www.who.int/drugresistance/documents/surveillancereport/en/.

SOURCE BD - Canada

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease

Survival estimates from the EMPA-REG OUTCOME^® trial data demonstrate potential long-term benefit of empagliflozin on life expectancy of adults with type 2 diabetes and cardiovascular disease¹

BURLINGTON, ON and TORONTO, Nov. 6, 2018 /CNW/ - The journal Circulation published novel results based on data from the landmark EMPA-REG OUTCOME^® trial, which suggest that treatment with empagliflozin positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease. Using actuarial methods*, and assuming that the demonstrated beneficial effects of empagliflozin remain consistent with long-term use, empagliflozin was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo.²

In an analysis of data from 7,020 patients included in the EMPA-REG OUTCOME^® trial, estimated life expectancy increased across all ages when adults were treated with empagliflozin as compared to those treated with placebo. Specifically, estimated mean survival in people aged 45 years was 32.1 years with empagliflozin versus 27.6 years with placebo, resulting in a mean survival difference of 4.5 years. In people aged 50, 60, 70 and 80 years old, the mean survival difference with empagliflozin compared to placebo was an additional 3.1 years, 2.5 years, 2 years and 1 year, respectively.³

"Studies show that people with diabetes develop heart disease up to 15 years earlier and have more heart failure than individuals without diabetes. This results in a substantial reduction of life expectancy in patients with diabetes especially when they have heart disease," says Dr. David Fitchett, cardiologist at St Michael's Hospital in Toronto, and a coauthor of the Circulation paper. "Our research indicates empagliflozin can prevent an early death in patients with diabetes, extending life expectancy by as much as 4.5 years."

The primary EMPA-REG OUTCOME^® trial results, published in the New England Journal of Medicine in September 2015, demonstrated a 38 percent relative risk reduction in cardiovascular death and a 32 percent relative risk reduction in all-cause mortality with empagliflozin in people with type 2 diabetes and established cardiovascular disease, compared with placebo, over a period of 3.1 years.⁴Modelling based on the EMPA-REG OUTCOME^® trial data was used to quantify the potential benefit of empagliflozin on residual life span.

"For people with type 2 diabetes and a history of heart disease, this analysis illustrates the benefit of treating with medication that not only lowers glucose but reduces cardiovascular risk," says Dr. Jan Hux, President and CEO of Diabetes Canada. "Diabetes contributes to 30 per cent of strokes and 40 per cent of heart attacks in this country, which is why Diabetes Canada has updated its guidelines in recent years to reflect the importance of identifying and managing cardiovascular risk."

*Actuarial methods refer to the statistical techniques and analysis used to prepare mortality and other analytical tables

About Diabetes and Cardiovascular Disease
Canada has the second highest rate of type 2 diabetes in the developed world,⁵ with over 3.5 million Canadians currently living with the disease, and another seven million at risk of diagnosis.⁶ Type 2 diabetes is the most common form of diabetes, responsible for around 90 percent of diabetes.⁷

Due to the complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, cardiovascular disease is a major complication and the leading cause of death associated with diabetes.^{8, 9, 10} Research from the recent My Heart Matters survey reveals that, although most Canadians with type 2 diabetes (93 per cent) feel they are knowledgeable about their disease management, one in two are unaware their diabetes alone significantly increases the risk of heart attack, heart failure and stroke.^{11, 12}

Having a history of diabetes at age 60 can shorten a person's life span by as much as six years compared with someone without diabetes. And having both diabetes and a history of heart attack or stroke at age 60 can shorten a person's life span by as much as 12 years compared with someone without these conditions.¹³

Diabetes Canada recommends the use of agents that have been proven to reduce the risk of cardiovascular events for patients with type 2 diabetes and established cardiovascular disease (such as empagliflozin).¹⁴

About the EMPA-REG OUTCOME^® trial¹⁵The EMPA-REG OUTCOME^® trial was a long-term, multicentre, randomized, double-blind, placebo-controlled trial of more than 7,000 people from 42 countries with type 2 diabetes at high risk for cardiovascular events.

The trial assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The overall safety profile of empagliflozin was consistent with that of previous trials.

About Empagliflozin
Empagliflozin is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in the label in several countries.^{16, 17, 18}

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body's blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME^® trial.

Empagliflozin is not approved for people with type 1 diabetes.

About Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centres on compounds representing several of the largest diabetes treatment classes. The alliance leverages the strengths of two of the world's leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of people with diabetes and stand together to focus on patient needs. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributed to the alliance. For more information about the Alliance visit www.boehringer-ingelheim.ca or www.lilly.ca.

About Boehringer Ingelheim (Canada) Ltd.
Improving the health and quality of life of patients is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. Research and development expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.ca or in our annual report: http://annualreport.boehringer-ingelheim.com.

About Eli Lilly Canada
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.

Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.

___________________________

¹ Claggett B, et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation. 2018;138:1599-1601

² Claggett B, et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation. 2018;138:1599-1601

³ Claggett B, et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation. 2018;138:1599-1601

⁴ Zinman B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-2128.

⁵ Canadian Institute for Health Information. International Comparisons: A Focus on Diabetes. November 4, 2015.

⁶ Diabetes Canada. "Diabetes in Canada". Backgrounder, March 2018. Available at: https://www.diabetes.ca/getmedia/6960f8d5-0869-4233-8ac2-6c669dae7c59/2018-Backgrounder-Canada_KH_AB_KB-edited-13-March-2018_2.pdf.aspx

⁷ Diabetes Canada. "Types of Diabetes". Diabetes, 2018. Available at: https://www.diabetes.ca/about-diabetes/types-of-diabetes

⁸ Diabetes Canada. "Complications". Diabetes and You, 2018. Available at: https://www.diabetes.ca/diabetes-and-you/complications/heart-disease-stroke

⁹ Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes & Vascular Disease. 2013;13(4):192–207.

¹⁰ Morrish NJ, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S14–21.

¹¹ Environics Research Group. "My Heart Matters Survey": Online survey conducted among 1,500 Canadians over 18 years of age was completed online between April 13 and May 4, 2018. Slide 5. Table S9 (row 293) in 2018.

¹² Environics Research Group. "My Heart Matters Survey": Online survey conducted among 1,500 Canadians over 18 years of age was completed online between April 13 and May 4, 2018. Slide 11.

¹³ The Emerging Risk Factors Collaboration. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52-60.

¹⁴ Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1-S325.

¹⁵ Zinman B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-2128.

¹⁶ Jardiance Product Monograph. Boehringer Ingelheim (Canada) Ltd. April 16, 2018. Last accessed August 2018.

¹⁷ European Summary of Product Characteristics Jardiance^®, approved May 2018. Data on file.

¹⁸ Jardiance^® (empagliflozin) tablets U.S. Prescribing Information. Available at: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf

SOURCE Boehringer Ingelheim (Canada) Ltd.

ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease

Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer

TORONTO and CAMBRIDGE, MA, Nov. 6, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today issued a narrated scientific white paper titled: "The critical importance of selectivity when developing antibody therapies for Alzheimer's disease." The white paper highlights the lessons learned from more than 15 years of drug development for Alzheimer's disease (AD) and why selectively targeting its root cause, now understood to be the toxic oligomer, is the most promising therapeutic approach. The presentation is available on the company's website at https://bit.ly/2zpPtpq

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

In this presentation, Dr. James Kupiec, ProMIS Chief Medical Officer, discusses why selectively targeting toxic oligomers (known as pathologic, misfolded proteins) is critical when developing medicines for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and ALS (amyotrophic lateral sclerosis). Dr. Kupiec outlines why PMN310, ProMIS' next-generation antibody, has the potential to become a best-in-class therapy among antibody treatments for AD. The paper also discusses design considerations for ProMIS' first clinical trial with PMN310, highlighting the use of novel biomarkers to capture potential early signs of efficacy of PMN310.

"Over the last dozen years, scientists across the Alzheimer's disease research community have come to recognize that it is the toxic oligomer form of amyloid beta (Aβ), and not the other forms such as Aβ monomers and plaque, that initiates the process of brain cell death in Alzheimer's, ultimately leading to the symptoms associated with this devastating disease", commented Dr. Kupiec. "Recent scientific data indicate that a best-in-class antibody therapeutic for Alzheimer's disease should target toxic oligomers without binding to non-toxic forms of Aβ."

Results of preclinical evaluations clearly indicate PMN310 strongly and preferentially binds the toxic oligomers from humans with Alzheimer's disease, and it is therefore highly selective. Contrary to current antibody candidates in development, PMN310 as designed does not bind to Aβ monomers nor plaques or vascular deposits of amyloid.

"Owing to its highly selective binding to toxic oligomers, we do not anticipate observing a dose-limiting side effect such as brain swelling; and because of its unique selectivity, therapeutic doses would not be wasted on superfluous targets. Accordingly, we hope to demonstrate a greater clinical benefit than other Aβ-directed antibodies currently showing encouraging results in clinical trials", stated Dr. Kupiec.

Potential partners and members of the Alzheimer's disease community can access both the narrated white paper and a written transcript directly on the ProMIS Neurosciences website or at https://bit.ly/2zpPtpq

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information about ProMIS Neurosciences, please consult the Company's website at: www.promisneurosciences.com

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE ProMIS Neurosciences Inc.

For further information:

For media inquiries, please contact: Shanti Skiffington, shanti.skiffington@gmail.com, Tel. 617 921-0808; For Investor Relations please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, nick@alpineequityadv.com, Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.goldstein@promisneurosciences.com

rock-it promotions adds Dr. Martens to its roster

TORONTO, ON — rock-it promotions, named one of Canada’s fastest growing companies by Growth 500 three years in a row, today announced Dr. Martens as their latest client win. Following a competitive review, the agency will manage all public relations activity in Canada for the global footwear brand.

As agency of record, rock-it promotions will spearhead Dr. Martens' overall PR strategy within Canada, conduct national media relations, manage and execute events, facilitate influencer engagement and celebrity gifting, and manage brand partnerships.

“We’re very excited to partner with this globally recognized and respected footwear brand,” said Debra Goldblatt-Sadowski, President and Founder of rock-it promotions. “We could not be more proud to work alongside a brand designed for people who possess a proud sense of self-expression and we look forward to sharing Dr. Martens exciting new collections and upcoming campaigns.”

“We’re thrilled to return to Canada in a larger PR capacity and focus efforts on the Canadian market,” said Sara LaHaie, US Brand Marketing and PR Manager, Dr. Martens. “We look forward to partnering with rock-it promotions, who demonstrated a strong understanding of the authenticity and diversity of the Dr. Martens brand, as well as the media and influencer landscape in this market.”

About rock-it promotions
Recognized as one of Canada’s leading lifestyle public relations firms, rock-it promotions is a full-service PR agency specializing in media relations, event planning, social media, launch events, press tours, sponsorship and partnerships and much more. The firm specializes in working with brands in a wide variety of industries including fashion, beauty, entertainment, food & beverage, hospitality, and travel & tourism. Current clients include adidas, GUESS, The JUNO Awards, L’Oréal Paris, Casper, Club Med, Toronto Fashion Week and Yorkville Village to name a few. Additionally, rock-it promotions operates two complementary divisions: Fourth Floor Management, a social influencer management arm that represents more than 20 of Canada’s most renowned and respected creative minds of the influencer community; and Tastemakers, a product placement company that pioneered the gifting suite concept in Canada and has been running its coveted lounge for the past 14 years, now called Suite on the Sixth.

About Dr. Martens
The first pair of Dr. Martens boots rolled off the production line on April 1, 1960. With its trademark yellow stitch, grooved sole and heel-loop, it was a boot for workers, initially worn by postmen and policemen; comfortable, durable and lightweight in comparison to its competitors at the time. Throughout Dr. Martens history, the brand has been adopted and subverted by diverse individuals, musicians, youth cultures and tribes. These are the people who stand out from the crowd and their journey of self-expression has always been accompanied by a pair of DM’s. The simple silhouette allows people to customize each pair; whilst on a utilitarian level their famous durability and comfort make them ideal footwear for the world of gigs and street fashion. On an emotional level, they are a flag of attitude and empowerment. The Northamptonshire factory where it all began still exists to this day, in the village of Wollaston. A specific range of ‘Made In England’ products are manufactured here by a small, close-knit team of people schooled in traditional shoe-making and the unique process that makes Dr. Martens like no other shoe on earth.

Twitter: @rockitpromo @drmartens
Instagram: @rockitpromo @drmartensofficial
Flickr: flickr.com/photos/rockitpromo
Website: www.rockitpromo.com , www.drmartens.com
To stay up-to-date on the latest rock-it news, click here to receive event invites, press releases and more.

20th Anniversary of National Aboriginal AIDS Awareness Week

Leading Indigenous Voice Faces Funding Impact on HIV Programs

OTTAWA, Nov. 6, 2018 /CNW/ - The Canadian Aboriginal AIDS Network (CAAN) announces Indigenous leadership and their supporters will celebrate its 20^thAnniversary of Aboriginal AIDS Awareness Week on November 29, 2018 in Ottawa, ON with a Parliamentary Breakfast followed by December 1 – 6, 2018events across the country (Vancouver, Edmonton, Peace River, Grande Prairie, Saskatoon, Winnipeg and more) to unite an Indigenous response to HIV and AIDS in a similar theme to World AIDS Day: Health For All – Know Your Status.

Ottawa November 29 Keynote: Hon. Jane Philpott, Minister of Indigenous Services
Peace River Correctional Centre event includes an open dialogue on Prison Needle Exchange Program with incarcerated inmates.
Vancouver event focus on Harm Reduction for Indigenous peoples leaving Federal Institutions in Pacific Region.
Indigenous peoples are over-represented in the HIV epidemic 2.7 times higher than other Canadians.

This series of events will connect Indigenous organizations, government partners, health care providers, and community leaders as they share lessons learned in order to create community readiness and culturally safe approaches to wholistic testing, care and treatment.

For over 20 years Aboriginal AIDS Awareness Week has provided HIV prevention, treatment and support resources and worked with Indigenous communities to empower them to address infectious diseases. In addition, CAAN's Promising Practices documentaries have received awards and accolades and Comcast has acquired global distribution.

The annual campaign is supported by CAAN's network which spans over 400 individuals and AIDS services partners; along with international alliances in 11 countries.

Aboriginal AIDS Awareness Week 2018 will also act as a platform for CAAN to continue to lobby for an urgent review of the HIV and Hepatitis C Community Action Fund, which has left so many long-standing organizations crippled by reduced funding or no funding. CAAN is experiencing the harsh impact of a 46% funding cut from the Community Action Fund.

"CAAN's severely reduced funding decimates the leading voice of First Nations, Inuit, and Métis peoples living with HIV or AIDS and will have severe consequences on both Indigenous health and reconciliation," states Ken Clement, CEO of Canadian Aboriginal AIDS Network. "We struggle to identify and support the newly funded groups in order to add an Indigenous voice to their work, and with our work we face losing the momentum we've made to eradicate the spread of HIV."

The Canadian Aboriginal AIDS Network and its launch co-hosts, Canadian Global Health All-Parliamentary Caucus HIV TB & Malaria, Interagency Coalition on AIDS and Development (ICAD), and Pauktuutit Inuit Women's Association of Canada invite you to participate in Aboriginal AIDS Awareness Week as it addresses different aspects of HIV prevention in a manner that reflects Indigenous cultures and traditional knowledge, and also the unique social, spiritual, economic and political needs of key populations.

For more information, Schedule of Events or to RSVP, visit: www.aboriginalaidsawareness.com

About CAAN www.caan.ca
The Canadian Aboriginal AIDS Network (CAAN) is a non-profit organization that leads a collective response to protect the wholistic wellness of First Nation, Inuit and Métis peoples impacted by HIV, hepatitis C and related diseases and issues, such as mental health, addictions and aging. Through research and programming, it informs and influences public health policy from an Indigenous worldview and advances self-determination to address health determinants with Indigenous traditions, values and knowledge.

About ICAD www.icad-cisd.com/

About Pauktuutit http://pauktuutit.ca/
National non-profit organization representing all Inuit women in Canada.

SOURCE Canadian Aboriginal AIDS Network (CAAN)

Wanderlust Launches “Passport”: a Global Events Membership for the Mindful Traveler

One-Time Purchase Grants Admission to All 2019 Wanderlust Events plus Member-Only Benefits

Passport Goes on Sale November 23, 2018

New York, NY (November 5, 2018) – Wanderlust, producer of the largest series of yoga lifestyle events in the world, continues the celebration of its 10-year anniversary by announcing the creation of Wanderlust Passport. Passport grants entry to all 2019 Wanderlust events—over 50 events in 20 countries on 5 continents—for one price. As your personal gateway to the outdoor adventures, diverse styles of yoga, restorative meditation, unique musical experiences and more, Passport instantly makes you a part of the global mindful movement, with perks, surprises and delights. For more information, please visit www.wanderlust.com/passport/

“A passport is a symbol of our personal wanderlust, our innate desire to travel and roam,” says Sean Hoess, CEO of Wanderlust. “We’ve always sought to incorporate adventure and local cultural experiences into our events as Wanderlust has spanned the globe, and we are excited to offer these experiences to mindful nomads everywhere at an affordable price.”

What is included in Wanderlust Passport?

Access to all 2019 Wanderlust events. This includes Wanderlust’s signature 4-day festivals and Wanderlust 108 “mindful triathlons” as well as two brand new event types: 2-day festivals, featuring immersive yoga, fitness and wellness programming and food experiences in urban parks across the US, and Immersions, a 1-day deep dive into expert-led topical workshops.

50% off Wellspring. Set in Palm Springs, CA and featuring the world’s leading innovators, teachers and socially-conscious companies, Wellspring is one part Wanderlust festival and one part ideas foundry.
Dedicated email and phone support to help with all event logistics and details.

Unlimited activity scheduling at all Wanderlust festivals.

A premium welcome kit suitable for gifting.

Access to an invite-only Facebook group.

Exclusive benefits and surprises.

The Wanderlust Passport will go on sale November 23, 2018—Black Friday—for $595 USD. Prices will rise incrementally throughout the year.

More information about the Wanderlust Passport can be found here: www.wanderlust.com/passport/

More information about all Wanderlust events can be found here: https://wanderlust.com/events/

About Wanderlust:
Wanderlust Holdings, LLC is a global yoga lifestyle company founded in 2009. Our mission is to help you find your true north—to live a healthy and inspired life. Wanderlust’s events encompass Wanderlust Festival, the world’s leading multi-day yoga and music festivals, Wanderlust 108, a one-day “mindful triathlon” taking place in urban parks across the globe, and Wellspring, a first-of-its-kind wellness gathering featuring the world’s leading innovators, teachers and socially-conscious companies. In 2012, Wanderlust opened the first of five Wanderlust yoga studios, culminating in the 2015 opening of Wanderlust Hollywood, a 10,000 square foot center in Los Angeles, CA offering yoga and meditation classes, a world-class organic restaurant, and a full-featured performance venue. In 2018, Wanderlust earned B Corporation Certification, meeting rigorous standards for social and environmental performance, ethics, accountability, and transparency in business.

Become a fan of Wanderlust at

Facebook www.facebook.com/wanderlust
Twitter www.twitter.com/wanderlustfest
Instagram http://instagram.com/wanderlustfest
YouTube http://www.youtube.com/user/WanderlustFestival

Style Guide: Festive Feels with GUESS

Let’s face it – the holidays can be hard on your schedule and wallet. With dinners, parties and events day after day, finding the perfect outfit can seem impossible. Rest assured, GUESS is here to help. With the trendiest styles for this season, GUESS will keep you feeling and looking great for all of your festivities. Scroll down to see a few of our favourite winter-ready and festive looks!

Get the look:
(L to R) Ellison Logo Beanie, $34.00. Amanda Cerny Logo Band Sports Bra, $34.00. Amanda Cerny Logo Band Boy Brief, $17.00. Amanda Cerny Red Cropped Fleece Hoodie, $69.00. Amanda Cerny Red Lace-up Fleece Sweatpants, $79.00. Kaden Chenille Mitten Gloves, $30.00. Varsity Pop Quilted Belt Bag, $78.00. Hype Logo Low Top Sneakers, $79.00

Winter mornings can be rough - who are we kidding? Mornings in general are rough. To get you through those extra cold ones, layer up and stay bundled without sacrificing an ounce of style. Slip into an ultra-soft two-piece tracksuit while you lounge around the house watching your favourite holiday movies. Need to step out and pick up some snacks? Throw on a knit toque along with some black kicks, matching pack and fingerless gloves to complete your casual comfy look!

Get the look:
(L to R) GUESS Originals Drawstring Flap Backpack, $90.00. GeeGee Quilted Faux-Leather Booties, $159.00.Off The Shoulder Fringe Mabel Sweater*, $98.00. Sexy Curve Jeans*, $118.00. Phoebe Faux-Fur Collar Coat, $198.00. Ellison Logo Beanie, $34.00.
*Available 1/1

Sweater weather is finally upon us and we couldn't be happier! It’s time for all those fun winter activities we have been waiting for – and comfy knits! Stroll the streets in a detailed sweater and distressed jeans as you search for the perfect gifts for everyone on your list. Amp up the wow factor by pairing this ensemble with a faux fur jacket and a cherry red backpack. Keep the faux fur coming with a sleek set of lace-up fur booties to keep your look simple but chic for this holiday season!

Get the look:
(L to R) Dessie Fur Jacket*, $198.00. Silver-Tone Analog Mesh Watch, $95.00. Zafira Over-the-Knee Boots, $169.00. Lennox Cold-Shoulder Sweater, $79.00. Jenny High-Rise Moto Skirt, $98.00. Silver-Tone Wire Hoop Earrings, $25.00. Kamryn Tote, $120.00.
*Available 12/1

Workwear in the winter is never easy – with the cold breeze and dark skies, finding something to spice up your wardrobe, while staying warm, is a necessity. Nothing says hot like a turtle neck knit and leather mini. Keep those bare legs chic and covered in your favourite pair of knee-high boots (the ultimate winter fave!). Toss on a coloured faux fur as your statement piece, accessorizing the ensemble accordingly. This look is guaranteed to turn some heads at the office.

Get the look:
(L to R) Farrah Gold-Tone Disc Earring, $48.00. Starry Night Cross Body Clutch, $75.00. One-Girl Knitted Sock Booties, $159.00. Maria D-Ring Belted Coat, $218.00. Bijou Maxi Dress*, $138.00.
*Available 12/1

If you want to be the belle of the ball for your parties, do we have the perfect look for you! Wow your family, friends and colleagues in a stunning mustard coloured dress (who says the holidays are just for red and green?). Slip on a pair of knitted sock booties and accessorize with all things gold - accenting your outfit with a black leather crossbody and a dashing pair of gold earrings. Ensure your outerwear is just as breathtaking as your outfit in a bright winter white canvas coat to really make you a star.

Get the look:
(L to R) Mae Flirty Jacket*, $148.00. Laurele Platform Peep-Toe Heels, $129.00. Jamison Romper*, $148.00. Dark Romance Duster Earrings, $32.00. Fall In Love Studded Crossbody, $85.00.
*Available 12/1

The final stop on the holiday list is New Year’s Eve: your big entrance into 2019. They say how you spend your New Year’s says everything about how the year will go, so make sure you’re spending it right! Dress to the nines in a fun n’ flirty sequin romper and get ready to steal the show. Pair the piece with statement earrings, a sleek leather jacket and studded purse. Finish the look off with a pair of stylish but comfy heels, since we know you will be dancing all the way to 2019. Now you’re ready to start the year off with a bang!

For more holiday inspiration, visit GUESS.ca.
Website: GUESS.ca
Twitter: @GUESS
Instagram: @GUESS
Facebook: GUESS
Hashtag: #LoveGUESS

Premier Health Group Inc. Announces Plans to Enter Canadian Pharmacy & Drug Store Market

VANCOUVER, Nov. 5, 2018 /CNW/ - Premier Health Group (CSE: PHGI) (CSE: PHGI.CN) (OTCQB: PHGRF) (Frankfurt: 6PH) (the "Company" or "Premier Health"), a Company focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry, is pleased to announce that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019.

"Pharmacy is a critical component in our commitment to providing patients with best in class primary care that is accessible and efficient in its delivery. Having the ability to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients with ease, and having it as a part of our comprehensive technology solution for primary care, is something we are very excited to roll-out to patients," said Dr. Essam Hamza, CEO of Premier.

The Company is actively reviewing a pipeline of additional pharmacy partners which include bricks and mortar locations for acquisition and strategic new retail opportunities for pharmacies. "It is our position that the emergence of technology such as the ability for patients to electronically send their prescription(s) to a pharmacy for fulfillment and pick up at a later time or delivery directly to them at home or work will result in increased patient and consumer enrollment in apps that offer this type of functionality," added Dr.Hamza.

The Canadian retail pharmacy market is estimated to be $44 billion (Source: IBISWorld). It is expected the industry sector will continue to allow for favourable economics for pharmacy operators as baby boomer's demand increases for prescriptions and operators expand scope of practice to include preventative services.

The Company expects to provide additional updates on acquisitions in Q4-18 and Q1-19.

ON BEHALF OF THE BOARD OF DIRECTORS
"Dr. Essam Hamza, MD"
Chief Executive Officer

About Premier Health

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are developing innovative health care approaches that combine human skill based expertise with emerging technologies, and will set the gold standard for services in locations of interest worldwide. Premier Health's subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The HealthVue team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.

Cautionary Statements

This news release contains forward-looking statements that are based on Premier Health's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Premier Health believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Premier Health undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Premier Health Group Inc.

For further information:

Premier Health Group Inc., Email: investors@healthvue.com, +604-807-8815, www.healthvue.com

LANCORA™ (ivabradine) now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure

LAVAL, QC, Nov. 5, 2018 /CNW Telbec/ - Servier Canada Inc. is pleased to announce that following Quebec and Saskatchewan, LANCORA™ is now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure.

Logo: Servier Canada Inc. (CNW Group/Servier Canada Inc.)

LANCORA™ can be prescribed and reimbursed for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (LVEF) (≤35%) in adult patients with New York Heart Association (NYHA) classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute (bpm), to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with standard chronic heart failure therapies. See individual formulary listings for province specific criteria^i,ii.

Over 600 000 Canadians are living with heart failure and 50 000 are diagnosed with the condition every year. Heart failure is a major cause of illness and disability, long and frequent hospital stays and premature death. Heart failure is a complex and incurable condition, resulting in the heart not being able to pump sufficient blood to meet the body's demandsⁱⁱⁱ.

"Increasing access to innovative drugs that not only save lives but also reduce the risk of hospitalization is a major advancement for heart failure patients but also their families and caregivers" said Dr Peter Liu, Chief Scientific Officer and Vice President of Research at the University of Ottawa Heart Institute.

"We are very pleased that patients in Ontario covered by the Ontario Public Drug Program and patients in BC covered by PharmaCare will now have access to the benefits of LANCORA™. LANCORA™ has already been included in the Drug Benefit plans of Quebec and Saskatchewan, and we continue to work with the other provinces so that across Canada, heart failure patients will have equal access to LANCORA™" said Frederic Fasano, Chief Executive Officer of Servier Canada. "Servier is committed to therapeutic progress to serve patient's needs, all of our activities are centered on this objective."

About LANCORA™
LANCORA™ (ivabradine) is indicated for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (≤ 35%) in adult patients with NYHA Classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute, to reduce the incidence of cardiovascular mortality and hospitalisations for worsening heart failure.^iv

About Servier Canada
Servier Canada Inc. is an affiliate of the independent French Servier Group. Our mission is to provide the Canadian medical community and its patients with innovative therapeutic solutions. As such, Servier Canada collaborates with various players in the healthcare system including researchers, entrepreneurs and innovators. In addition to these research partners, the Canadian International Center for Therapeutic Research (ICTR) is dedicated to clinical development with more than 50 studies conducted throughout Canada over the last 10 years.

More information is available at www.servier.ca

____________________
i. https://www.formulary.health.gov.on.ca/formulary/
ii. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/special-authority#Druglist
iii. The Burden of Heart Failure: 2016 report on the health of Canadians. https://www.heartandstroke.ca accessed July 18th, 2018
iv. LANCORA Product Monograph, May 2018

SOURCE Servier Canada Inc.